Search

everythinglearnresearchcommunity

for

Search:↓

Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.

Male pattern baldness may predict prostate cancer risk.

Steroid sex hormones activate matriptase in prostate cancer cells but not in breast cancer cells.

5α-reductase inhibitors may prevent prostate cancer but could also raise the risk of more severe cancers.

Finasteride might lower the risk of low-grade prostate cancer but not high-grade cancer, while alpha-blockers might reduce high-grade cancer risk.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

A new compound was effective for imaging prostate cancer in rats.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

The document suggests that blocking sweat glands with antiperspirants might allow skin-generated hormones to be absorbed, possibly increasing breast and prostate cancer risk.

Higher DHT in male baldness may protect against prostate cancer.

The study found no link between baldness patterns and androgen levels in men with benign prostate enlargement or prostate cancer.

Suppressing certain hormones might help prevent prostate cancer.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Early balding at 40 increases prostate cancer risk.

Early balding, especially frontal, increases prostate cancer risk; more research needed.

Hair loss gene linked to prostate issues.

Finasteride use may increase the risk of male breast cancer.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Men with a certain baldness pattern at age 40-50 may have a higher risk of aggressive prostate cancer.

CEC levels may be a useful marker for predicting prostate cancer progression.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.

Nanoparticles improve cancer treatment by reducing side effects and targeting cancer cells better.

Scalp cooling helps prevent hair loss during chemotherapy, and minoxidil aids regrowth.

5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.